Selected article for: "following year and oral prednisolone"

Author: Jartti, Tuomas; Smits, Hermelijn H.; Bønnelykke, Klaus; Bircan, Ozlem; Elenius, Varpu; Konradsen, Jon R.; Maggina, Paraskevi; Makrinioti, Heidi; Stokholm, Jakob; Hedlin, Gunilla; Papadopoulos, Nikolaos; Ruszczynski, Marek; Ryczaj, Klaudia; Schaub, Bianca; Schwarze, Jürgen; Skevaki, Chrysanthi; Stenberg-Hammar, Katarina; Feleszko, Wojciech
Title: Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments
  • Document date: 2018_11_25
  • ID: 4svg09dt_36
    Snippet: There are only a few agents targeting the inhibition of the attachment of RV to the cell or uncoating viral RNA, and their clinical applicability is continuously questioned due to adverse events (pleconaril, vapendavir) or drug resistance (amantadine, rimantadine). 72, 73 Prednisolone: In two separate randomized trials, oral corticosteroid, prednisolone, has been shown to increase the time to the physician-confirmed relapse within the following y.....
    Document: There are only a few agents targeting the inhibition of the attachment of RV to the cell or uncoating viral RNA, and their clinical applicability is continuously questioned due to adverse events (pleconaril, vapendavir) or drug resistance (amantadine, rimantadine). 72, 73 Prednisolone: In two separate randomized trials, oral corticosteroid, prednisolone, has been shown to increase the time to the physician-confirmed relapse within the following year by 20%-30%

    Search related documents:
    Co phrase search for related documents
    • adverse event and follow year: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adverse event and randomized trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and time increase: 1, 2
    • clinical applicability and randomized trial: 1, 2, 3
    • drug resistance and randomized trial: 1, 2, 3, 4, 5, 6
    • drug resistance and rimantadine amantadine: 1, 2, 3, 4, 5
    • drug resistance and rimantadine amantadine drug resistance: 1
    • drug resistance and time increase: 1, 2
    • follow year and randomized trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • follow year and time increase: 1, 2, 3, 4, 5
    • physician confirm and randomized trial: 1
    • randomized trial and separate randomized trial: 1, 2
    • randomized trial and time increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25